{
    "startDate": "2020-04-01",
    "endDate": "2020-06-30",
    "year": "2020",
    "quarter": "Q2",
    "symbol": "CLBS",
    "data": {
        "bs": [
            {
                "label": "Right-of-use assets",
                "concept": "OperatingLeaseRightOfUseAsset",
                "unit": "usd",
                "value": 731000
            },
            {
                "label": "Operating lease liabilities -- current",
                "concept": "OperatingLeaseLiabilityCurrent",
                "unit": "usd",
                "value": 349000
            },
            {
                "label": "Operating lease liabilities",
                "concept": "OperatingLeaseLiability",
                "unit": "usd",
                "value": 794000
            }
        ],
        "cf": [],
        "ic": [
            {
                "label": "Research and development",
                "concept": "ResearchAndDevelopmentExpense",
                "unit": "usd",
                "value": 1818000
            },
            {
                "label": "General and administrative",
                "concept": "SellingGeneralAndAdministrativeExpense",
                "unit": "usd",
                "value": 2474000
            },
            {
                "label": "Total operating expenses",
                "concept": "OperatingExpenses",
                "unit": "usd",
                "value": 4292000
            },
            {
                "label": "Operating loss",
                "concept": "OperatingIncomeLoss",
                "unit": "usd",
                "value": 4292000
            },
            {
                "label": "Investment income, net",
                "concept": "OtherNonoperatingIncomeExpense",
                "unit": "usd",
                "value": 22000
            },
            {
                "label": "Total other income",
                "concept": "NonoperatingIncomeExpense",
                "unit": "usd",
                "value": 22000
            },
            {
                "label": "Loss before benefit from income taxes and noncontrolling interests",
                "concept": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
                "unit": "usd",
                "value": 4270000
            },
            {
                "label": "Benefit from income taxes",
                "concept": "IncomeTaxExpenseBenefit",
                "unit": "usd",
                "value": 10872000
            },
            {
                "label": "Net income (loss)",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": 6602000
            },
            {
                "label": "Less - net income attributable to noncontrolling interests",
                "concept": "IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity",
                "unit": "usd",
                "value": 4000
            },
            {
                "label": "Net (loss) income attributable to Caladrius Biosciences, Inc. common stockholders",
                "concept": "NetIncomeLoss",
                "unit": "usd",
                "value": 6598000
            },
            {
                "label": "Caladrius Biosciences, Inc. common stockholders (in usd per share)",
                "concept": "EarningsPerShareBasicAndDiluted",
                "unit": "usd/shares",
                "value": 0.5
            },
            {
                "label": "Basic and diluted shares",
                "concept": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
                "unit": "shares",
                "value": 13151000
            }
        ]
    }
}